Corporate
2019.01.23
Formulation patent for Naldebain approved
New U.S. Patent Granted to Lumosa for Naldebain(R), a Long-acting Analgesic for Moderate to Severe Post-Operative Pain
Corporate
2018.08.30
Lumosa partner submitted clinical trial application for LT1001 in China
Lumosa Therapeutics Co., Ltd. (6535. TWO) (“Lumosa”) today announced that its partner, Syntano Technology Venture (“Syntano”), a subsidiary of the Haike group, has submitted Clinical Trial Application (CTA) to the China National Drug Administration (CNDA) for Lumosa’s long-acting analgesic injection, LT1001 (the product name used in Taiwan: Naldebain®) as a Class 5.1 New Drug. Lumosa will receive milestone payment correspondingly. Clinical trials for Class 5.1 (Imported New Drugs) require fewer subjects for confirmatory purpose, which would shorten the registration process for LT1001 to be launched in China.
Corporate
2018.06.08
LT1001 out-licensed to ASEAN Region
(Taipei, Taiwan. June 8, 2018) Following licensing of Naldebain®, a long acting analgesic injection (also referred as“LT1001”) to Skyline Vet Pharma for veterinary-use in North America, Australia and New Zealand markets earlier this year, Lumosa Therapeutics Co., Ltd. (“Lumosa”)( 6535. TWO) announced the signing of a license agreement with Amed Co., Ltd. (“Amed”) for its marketing and manufacture right in the ten countries of the Association of Southeast Asian Nations (ASEAN).
Corporate
2018.02.22
USPTO granted LT3001 patent
US Patent Granted for Lumosa's New Drug to Treat Acute Ischemic Stroke (Taipei, Taiwan. February 22, 2018) Lumosa Therapeutics (6535.TWO) is pleased to announce that USPTO has issued the US patent (No. US9890193) for the company's new drug candidate, LT3001, which is under development for the treatment of acute ischemic stroke. This is the second patent approval of LT3001 in a major market after the State Intellectual Property Office of China granted LT3001 patent in 2017. Intellectual property of LT3001 is now protected in the two largest pharmaceutical markets in the world, which enhanced the market value of LT3001.
Corporate
2018.01.16
Lumosa licenses CS011, an extended release analgesic injection, to SVP for animal use
Lumosa Therapeutics Licenses Long Acting Injectable Analgesic to Skyline Vet Pharma, Inc. for Use in Companion Animals
Corporate
2017.10.30
Lumosa invited to 2017 STAIR X
Lumosa was invited to the tenth Stroke Treatment Academic Industry Roundtable (STAIR X) held on October 23-24 in Washington D.C., USA, where top scientists and specialists gather to publish the latest research on cerebral stroke. Applications of neuroprotection agents on acute ischemic stroke were discussed during the STAIR conference. Neuroprotectants may protect the brain from ischemia and can be combined with thrombectomy to extend the "Golden Hour" and enhance treatment effect. Lumosa's LT3001 possess thrombolytic and neuroprotective functions and is currently under Phase 1 trial in the US.